Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Introduction and Overview of CAR T-Cell Therapy (14 mins)
  • CME
  • MOC

This segment provides an overview of CAR T-cell therapy, including brief discussions of underlying principles and best referral practices.
Michael R. Bishop, MD
Program Director
Daniel J. DeAngelo, MD, PhD
Noopur Raje, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
ABIM MOC: maximum of 1.5 Medical Knowledge MOC point(s)
Released: August 14, 2020 Expiration: August 13, 2021

This program is divided into short segments that you can review from the Activity landing page.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Review the biologic principles underlying CAR T-cell therapy, structure and function of the CAR, and the mechanism of action of CAR T-cells
  • Identify characteristics of patients that are appropriate for treatment with CAR T-cell therapy
  • Review the clinical trial data on CAR T-cell–based therapies for the treatment of patients with leukemia and lymphoma, and describe where CAR T-cell therapies might fit into the treatment landscape
  • Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with myeloma
  • Based on the current best evidence, implement strategies for managing toxicities associated with CAR T-cell therapy
  • Recall ongoing clinical trials evaluating CAR T-cell therapy for the treatment of leukemia, lymphoma, and myeloma to aid in the referral of appropriate patients

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Michael R. Bishop, MD

Professor of Medicine
Section of Hematology/Oncology
Director, Cellular Therapy Program
University of Chicago
Chicago, Illinois

Michael R. Bishop, MD, has disclosed that he has received honoraria from Agios, Celgene, Gilead Sciences/Kite, OptumHealth, Pharmacyclics, and Sanofi; has served on speaker bureaus for Agios, Celgene, Gilead Sciences/Kite, Pharmacyclics, and Sanofi; and has received consulting fees from CRISPR Therapeutics, Gilead Sciences/Kite, Juno, Novartis, and OptumHealth.

Faculty

Daniel J. DeAngelo, MD, PhD

Professor of Medicine
Department of Medicine
Harvard Medical School
Chief of the Division of Leukemia
Department of Medical Oncology
Division of Hematologic Malignancies
Dana‐Farber Cancer Institute
Boston, Massachusetts

Daniel J. DeAngelo, MD, PhD, has disclosed that he has received consulting fees from Amgen, Autolus, Axios, Blueprint, Forty Seven, Incyte, Jazz, Novartis, Servier, and Takeda and funds for research support from AbbVie, Blueprint, GlycoMimetics, and Novartis.
Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Noopur Raje, MD, has disclosed that she has received consulting fees from Amgen, Bristol-Myers Squibb, Caribou, Celgene, Immuneel, Janssen, Karyopharm, and Takeda and funds for research support from Bluebird Bio.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who treat and manage patients with leukemia, lymphoma, or myeloma who are candidates for CAR T-cell therapies.

Goal

The goal of this activity is to improve the knowledge of physicians and other healthcare providers of CAR T-cell therapies so they can confidently and competently integrate these treatments into their clinical practices.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 14, 2020, through August 13, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Latest evidence on effective management of chronic lymphocytic leukemia (CLL) using BTK inhibitors in this video from Clinical Care Options (CCO)

Danielle Brander, MD Nicole Lamanna, MD Jeff P. Sharman, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: September 16, 2020 Expired: September 15, 2021

Nicole Lamanna, MD, on modifying CLL treatment during COVID-19 pandemic, IVIg as COVID-19 prophylaxis, and the role of BTK inhibition, from CCO

Nicole Lamanna, MD Released: September 14, 2020

On-demand Webcast featuring experts’ review of evolving strategies for optimal treatment of patients with relapsed/refractory multiple myeloma in 2020

Shaji Kumar, MD
Program Director
Natalie S. Callander, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: September 14, 2020 Expired: September 13, 2021

Download this slideset from a CCO Live Meeting Series to review the latest evidence on selecting optimal management strategies for follicular lymphoma

John M. Burke, MD Peter Martin, MD Released: September 11, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Celgene Corporation
Legend Biotech USA Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?